Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Related Citations for PubMed (Select 24984333)

1.

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].

Vince A, Duvnjak M, Kurelac I.

Acta Med Croatica. 2013 Oct;67(4):329-38. Croatian.

PMID:
24984333
2.

Treatment for Hepatitis C Virus Infection in Adults [Internet].

Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

3.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
4.

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S.

J Hepatol. 2014 Mar;60(3):530-7. doi: 10.1016/j.jhep.2013.11.009. Epub 2013 Nov 19.

PMID:
24269472
5.

Current progress in the treatment of chronic hepatitis C.

Alexopoulou A, Papatheodoridis GV.

World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060. Review.

6.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

7.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21.

PMID:
24032626
8.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
9.

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.

Park C, Jiang S, Lawson KA.

J Clin Pharm Ther. 2014 Feb;39(1):14-24. doi: 10.1111/jcpt.12106. Epub 2013 Nov 16. Review.

PMID:
24237070
10.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
11.

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.

Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M.

J Viral Hepat. 2015 Feb;22(2):175-83. doi: 10.1111/jvh.12278. Epub 2014 Jul 10.

PMID:
25040391
12.

[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].

Makara M, Horváth G, Gervain J, Pár A, Szalay F, Telegdy L, Tornai I, Ujhelyi E, Hunyady B.

Orv Hetil. 2012 Mar 11;153(10):375-94. doi: 10.1556/OH.2012.29338. Hungarian.

13.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
14.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

15.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
16.

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.

QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214. Epub 2012 Nov 17.

17.

[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].

Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I.

Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893. Hungarian.

18.

Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.

Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L.

World J Hepatol. 2014 Sep 27;6(9):660-9. doi: 10.4254/wjh.v6.i9.660.

19.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
20.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.

J Infect. 2013 Jul;67(1):59-64. doi: 10.1016/j.jinf.2013.03.010. Epub 2013 Mar 28.

PMID:
23542783
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk